The Filings Report

Cytokinetics Inc.

CYTKNasdaqCIK 1061983Healthcare / Drug Manufacturersfiscal year ends December66 quarters since 2010

Revenue, Q3 FY2026
$48M
+2356.5% on Q3 FY2025
Net income
−$190M
+37.9% on Q3 FY2025
Free cash flow
−$125M
−6.7% on Q3 FY2025
Diluted EPS
$-1.37
+46.3% on Q3 FY2025
Revenue, TTM
$113M
trailing four quarters
Net margin, TTM
-686.6%
net income −$778M
Free cash flow, TTM
−$589M
−$572M less $17M capex
Cash and equivalents
$203M
long-term debt $244M, Sep 30, 2026
Shares, 12-month change
+13.9%
139M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$7.5B
at the close, buybacks

Latest quarter Q3 FY2026, filed November 4, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Cytokinetics Inc. reported revenue of $48M, +2356.5% on Q3 FY2025, and net loss of $190M (+37.9%). Operating margin was −351.3%. Free cash flow, operating cash flow less capital expenditures, was −$125M (−$124M less $700K). Diluted earnings per share were $-1.37.

Share price

Daily candlesticks from November 11, 2024 to November 6, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

CYTK daily priceSplit-adjusted, US dollars; an earnings release
Nov 6, 2026O $55.90 · H $56.51 · L $53.55 · C $53.69 · −3.35% on the dayOver the range: −10.96%, Nov 7, 2025 to Nov 6, 2026
$51$61$71$81$90Nov 25Jan 26Apr 26Jun 26Aug 26Nov 26

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of November 4, 2026.

Revenue and net incomeRevenueNet income
−$400M−$300M−$200M−$100M$0$100MQ4'22, Revenue: $2MQ4'22, Net income: −$137MQ4'22Q1'23, Revenue: $5MQ1'23, Net income: −$131MQ1'23Q2'23, Revenue: $867KQ2'23, Net income: −$129MQ2'23Q3'23, Revenue: $378KQ3'23, Net income: −$129MQ3'23Q4'23, Revenue: $2MQ4'23, Net income: −$137MQ4'23Q1'24, Revenue: $835KQ1'24, Net income: −$136MQ1'24Q2'24, Revenue: $249KQ2'24, Net income: −$143MQ2'24Q3'24, Revenue: $463KQ3'24, Net income: −$161MQ3'24Q4'24, Revenue: $17MQ4'24, Net income: −$150MQ4'24Q1'25, Revenue: $2MQ1'25, Net income: −$161MQ1'25Q2'25, Revenue: $67MQ2'25, Net income: −$134MQ2'25Q3'25, Revenue: $2MQ3'25, Net income: −$306MQ3'25Q4'25, Revenue: $18MQ4'25, Net income: −$183MQ4'25Q1'26, Revenue: $19MQ1'26, Net income: −$206MQ1'26Q2'26, Revenue: $29MQ2'26, Net income: −$199MQ2'26Q3'26, Revenue: $48MQ3'26, Net income: −$190MQ3'26−$400M−$300M−$200M−$100M$0$100MQ4'22, Revenue: $2MQ4'22, Net income: −$137MQ4'22Q1'23, Revenue: $5MQ1'23, Net income: −$131MQ1'23Q2'23, Revenue: $867KQ2'23, Net income: −$129MQ2'23Q3'23, Revenue: $378KQ3'23, Net income: −$129MQ3'23Q4'23, Revenue: $2MQ4'23, Net income: −$137MQ4'23Q1'24, Revenue: $835KQ1'24, Net income: −$136MQ1'24Q2'24, Revenue: $249KQ2'24, Net income: −$143MQ2'24Q3'24, Revenue: $463KQ3'24, Net income: −$161MQ3'24Q4'24, Revenue: $17MQ4'24, Net income: −$150MQ4'24Q1'25, Revenue: $2MQ1'25, Net income: −$161MQ1'25Q2'25, Revenue: $67MQ2'25, Net income: −$134MQ2'25Q3'25, Revenue: $2MQ3'25, Net income: −$306MQ3'25Q4'25, Revenue: $18MQ4'25, Net income: −$183MQ4'25Q1'26, Revenue: $19MQ1'26, Net income: −$206MQ1'26Q2'26, Revenue: $29MQ2'26, Net income: −$199MQ2'26Q3'26, Revenue: $48MQ3'26, Net income: −$190MQ3'26−$400M−$300M−$200M−$100M$0$100MQ4'22, Revenue: $2MQ4'22, Net income: −$137MQ1'23, Revenue: $5MQ1'23, Net income: −$131MQ1'23Q2'23, Revenue: $867KQ2'23, Net income: −$129MQ3'23, Revenue: $378KQ3'23, Net income: −$129MQ3'23Q4'23, Revenue: $2MQ4'23, Net income: −$137MQ1'24, Revenue: $835KQ1'24, Net income: −$136MQ1'24Q2'24, Revenue: $249KQ2'24, Net income: −$143MQ3'24, Revenue: $463KQ3'24, Net income: −$161MQ3'24Q4'24, Revenue: $17MQ4'24, Net income: −$150MQ1'25, Revenue: $2MQ1'25, Net income: −$161MQ1'25Q2'25, Revenue: $67MQ2'25, Net income: −$134MQ3'25, Revenue: $2MQ3'25, Net income: −$306MQ3'25Q4'25, Revenue: $18MQ4'25, Net income: −$183MQ1'26, Revenue: $19MQ1'26, Net income: −$206MQ1'26Q2'26, Revenue: $29MQ2'26, Net income: −$199MQ3'26, Revenue: $48MQ3'26, Net income: −$190MQ3'26

Net income losses drawn in red.

Free cash flow
−$200M−$150M−$100M−$50M$0$50MQ4'22, Free cash flow: −$101MQ4'22Q1'23, Free cash flow: −$123MQ1'23Q2'23, Free cash flow: −$123MQ2'23Q3'23, Free cash flow: −$96MQ3'23Q4'23, Free cash flow: −$74MQ4'23Q1'24, Free cash flow: −$130MQ1'24Q2'24, Free cash flow: −$101MQ2'24Q3'24, Free cash flow: −$102MQ3'24Q4'24, Free cash flow: −$67MQ4'24Q1'25, Free cash flow: −$137MQ1'25Q2'25, Free cash flow: −$132MQ2'25Q3'25, Free cash flow: −$117MQ3'25Q4'25, Free cash flow: −$148MQ4'25Q1'26, Free cash flow: −$151MQ1'26Q2'26, Free cash flow: −$164MQ2'26Q3'26, Free cash flow: −$125MQ3'26−$200M−$150M−$100M−$50M$0$50MQ4'22, Free cash flow: −$101MQ4'22Q1'23, Free cash flow: −$123MQ1'23Q2'23, Free cash flow: −$123MQ2'23Q3'23, Free cash flow: −$96MQ3'23Q4'23, Free cash flow: −$74MQ4'23Q1'24, Free cash flow: −$130MQ1'24Q2'24, Free cash flow: −$101MQ2'24Q3'24, Free cash flow: −$102MQ3'24Q4'24, Free cash flow: −$67MQ4'24Q1'25, Free cash flow: −$137MQ1'25Q2'25, Free cash flow: −$132MQ2'25Q3'25, Free cash flow: −$117MQ3'25Q4'25, Free cash flow: −$148MQ4'25Q1'26, Free cash flow: −$151MQ1'26Q2'26, Free cash flow: −$164MQ2'26Q3'26, Free cash flow: −$125MQ3'26−$200M−$150M−$100M−$50M$0$50MQ4'22, Free cash flow: −$101MQ1'23, Free cash flow: −$123MQ1'23Q2'23, Free cash flow: −$123MQ3'23, Free cash flow: −$96MQ3'23Q4'23, Free cash flow: −$74MQ1'24, Free cash flow: −$130MQ1'24Q2'24, Free cash flow: −$101MQ3'24, Free cash flow: −$102MQ3'24Q4'24, Free cash flow: −$67MQ1'25, Free cash flow: −$137MQ1'25Q2'25, Free cash flow: −$132MQ3'25, Free cash flow: −$117MQ3'25Q4'25, Free cash flow: −$148MQ1'26, Free cash flow: −$151MQ1'26Q2'26, Free cash flow: −$164MQ3'26, Free cash flow: −$125MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$100M$200M$300MQ4'22, Cash and equivalents: $66MQ4'22, Long-term debt: $64MQ4'22Q1'23, Cash and equivalents: $102MQ1'23, Long-term debt: $64MQ1'23Q2'23, Cash and equivalents: $69MQ2'23, Long-term debt: $62MQ2'23Q3'23, Cash and equivalents: $100MQ3'23, Long-term debt: $61MQ3'23Q4'23, Cash and equivalents: $113MQ4'23, Long-term debt: $58MQ4'23Q1'24, Cash and equivalents: $120MQ1'24, Long-term debt: $57MQ1'24Q2'24, Cash and equivalents: $190MQ2'24, Long-term debt: $93MQ2'24Q3'24, Cash and equivalents: $47MQ3'24, Long-term debt: $93MQ3'24Q4'24, Cash and equivalents: $95MQ4'24, Long-term debt: $93MQ4'24Q1'25, Cash and equivalents: $74MQ1'25, Long-term debt: $92MQ1'25Q2'25, Cash and equivalents: $75MQ2'25, Long-term debt: $159MQ2'25Q3'25, Cash and equivalents: $225MQ3'25, Long-term debt: $159MQ3'25Q4'25, Cash and equivalents: $123MQ4'25, Long-term debt: $246MQ4'25Q1'26, Cash and equivalents: $130MQ1'26, Long-term debt: $247MQ1'26Q2'26, Cash and equivalents: $255MQ2'26, Long-term debt: $248MQ2'26Q3'26, Cash and equivalents: $203MQ3'26, Long-term debt: $244MQ3'26$0$100M$200M$300MQ4'22, Cash and equivalents: $66MQ4'22, Long-term debt: $64MQ4'22Q1'23, Cash and equivalents: $102MQ1'23, Long-term debt: $64MQ1'23Q2'23, Cash and equivalents: $69MQ2'23, Long-term debt: $62MQ2'23Q3'23, Cash and equivalents: $100MQ3'23, Long-term debt: $61MQ3'23Q4'23, Cash and equivalents: $113MQ4'23, Long-term debt: $58MQ4'23Q1'24, Cash and equivalents: $120MQ1'24, Long-term debt: $57MQ1'24Q2'24, Cash and equivalents: $190MQ2'24, Long-term debt: $93MQ2'24Q3'24, Cash and equivalents: $47MQ3'24, Long-term debt: $93MQ3'24Q4'24, Cash and equivalents: $95MQ4'24, Long-term debt: $93MQ4'24Q1'25, Cash and equivalents: $74MQ1'25, Long-term debt: $92MQ1'25Q2'25, Cash and equivalents: $75MQ2'25, Long-term debt: $159MQ2'25Q3'25, Cash and equivalents: $225MQ3'25, Long-term debt: $159MQ3'25Q4'25, Cash and equivalents: $123MQ4'25, Long-term debt: $246MQ4'25Q1'26, Cash and equivalents: $130MQ1'26, Long-term debt: $247MQ1'26Q2'26, Cash and equivalents: $255MQ2'26, Long-term debt: $248MQ2'26Q3'26, Cash and equivalents: $203MQ3'26, Long-term debt: $244MQ3'26$0$100M$200M$300MQ4'22, Cash and equivalents: $66MQ4'22, Long-term debt: $64MQ1'23, Cash and equivalents: $102MQ1'23, Long-term debt: $64MQ1'23Q2'23, Cash and equivalents: $69MQ2'23, Long-term debt: $62MQ3'23, Cash and equivalents: $100MQ3'23, Long-term debt: $61MQ3'23Q4'23, Cash and equivalents: $113MQ4'23, Long-term debt: $58MQ1'24, Cash and equivalents: $120MQ1'24, Long-term debt: $57MQ1'24Q2'24, Cash and equivalents: $190MQ2'24, Long-term debt: $93MQ3'24, Cash and equivalents: $47MQ3'24, Long-term debt: $93MQ3'24Q4'24, Cash and equivalents: $95MQ4'24, Long-term debt: $93MQ1'25, Cash and equivalents: $74MQ1'25, Long-term debt: $92MQ1'25Q2'25, Cash and equivalents: $75MQ2'25, Long-term debt: $159MQ3'25, Cash and equivalents: $225MQ3'25, Long-term debt: $159MQ3'25Q4'25, Cash and equivalents: $123MQ4'25, Long-term debt: $246MQ1'26, Cash and equivalents: $130MQ1'26, Long-term debt: $247MQ1'26Q2'26, Cash and equivalents: $255MQ2'26, Long-term debt: $248MQ3'26, Cash and equivalents: $203MQ3'26, Long-term debt: $244MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed November 4, 2026.

Cytokinetics Inc. income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 4, 2026Q2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 27, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue48291918267217+2356.5%
Cost of revenue—————————
Gross profit—————————
Research and development999896110971109894+2.0%
Selling, general and administrative1131041059269665762+62.9%
Operating income(167)(179)(184)(178)(167)(112)(156)(139)−0.2%
Other income (expense)1614111110131415+55.2%
Pretax income—————————
Income tax—————————
Net income(190)(199)(206)(183)(306)(134)(161)(150)+37.9%
Diluted EPS ($)(1.37)(1.50)(1.67)—(2.55)(1.12)(1.36)—+46.3%
Diluted shares (millions)139*132*123*—120*119*118*——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed November 4, 2026.

Cytokinetics Inc. balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 4, 2026Q2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 27, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents203255130123225757495−9.8%
Short-term investments927910689760737783865981+25.7%
Total current assets1,1871,2088399179778879561,108+21.5%
Total assets1,8251,9251,2731,4251,4371,2261,2641,402+27.0%
Total current liabilities353181199202142131160180+148.6%
Long-term debt2442482472461591599293+53.9%
Total liabilities2,1462,0982,1002,0841,9581,5941,5301,537+9.6%
Stockholders’ equity(321)(173)(827)(660)(521)(369)(266)(135)+38.4%
Shares outstanding (millions)139139124123122120119118—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed November 4, 2026.

Cytokinetics Inc. cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 4, 2026Q2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 27, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow(124)(160)(145)(143)(108)(128)(132)(66)−15.4%
Capital expenditures14669461−92.5%
Free cash flow (CFO − capex)(125)(164)(151)(148)(117)(132)(137)(67)−6.7%
Depreciation and amortization44333222+36.2%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 26, 2026.

Income statement

Cytokinetics Inc. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 27, 2025FY2023ended Dec 31, 2023filed Feb 28, 2024FY2022ended Dec 31, 2022filed Mar 1, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 26, 2021FY2019ended Dec 31, 2019filed Mar 4, 2020FY2018ended Dec 31, 2018filed Mar 7, 2019FY2017ended Dec 31, 2017filed Mar 5, 2018FY2016ended Dec 31, 2016filed Mar 6, 2017FY2015ended Dec 31, 2015filed Mar 3, 2016FY2014ended Dec 31, 2014filed Mar 6, 2015FY2013ended Dec 31, 2013filed Mar 7, 2014FY2012ended Dec 31, 2012filed Mar 15, 2013FY2011ended Dec 31, 2011filed Mar 13, 2012FY2010ended Dec 31, 2010filed Aug 4, 2011FY2009ended Dec 31, 2009filed Aug 4, 2011FY2008ended Dec 31, 2008filed Mar 13, 2012FY2007ended Dec 31, 2007filed Mar 13, 2012FY2006ended Dec 31, 2006filed Mar 13, 2012FY2005ended Dec 31, 2005filed Mar 13, 2012FY2004ended Dec 31, 2004filed Mar 13, 2012FY2003ended Dec 31, 2003filed Mar 13, 2012FY2002ended Dec 31, 2002filed Mar 13, 2012FY2001ended Dec 31, 2001filed Mar 13, 2012FY2000ended Dec 31, 2000filed Mar 13, 2012FY1999ended Dec 31, 1999filed Mar 13, 2012
Revenue8818895705627321310629473184382——————————
Cost of revenue———————————————————————————
Gross profit———————————————————————————
Research and development416339330241160978689906046444936373840——————————
Selling, general and administrative28421517417897534031362820171512141416——————————
Operating income(612)(536)(496)(324)(186)(94)(99)(89)(113)19(37)(15)(34)(40)(48)(50)26——————————
Other income (expense)48522811055430000000(1)——————————
Pretax income———————(106)(128)16(38)(15)(34)(40)(48)(49)25——————————
Income tax00000000000000000——————————
Net income(785)(590)(526)(389)(215)(127)(122)(106)(128)16(38)(15)(34)(40)(48)(49)25(56)(49)(57)(42)(37)(33)(23)(16)(13)(7)
Diluted EPS ($)(6.54)(5.26)(5.45)(4.33)(2.80)(1.97)——(2.59)0.39(0.97)(0.41)——(4.32)*(4.62)*2.52*——————————
Diluted shares (millions)120*112*97*90*77*65*——49433936——12*11*10*——————————

Balance sheet

Cytokinetics Inc. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 27, 2025FY2023ended Dec 31, 2023filed Feb 28, 2024FY2022ended Dec 31, 2022filed Mar 1, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 26, 2021FY2019ended Dec 31, 2019filed Mar 4, 2020FY2018ended Dec 31, 2018filed Mar 7, 2019FY2017ended Dec 31, 2017filed Mar 5, 2018FY2016ended Dec 31, 2016filed Mar 6, 2017FY2015ended Dec 31, 2015filed Mar 3, 2016FY2014ended Dec 31, 2014filed Mar 6, 2015FY2013ended Dec 31, 2013filed Mar 7, 2014FY2012ended Dec 31, 2012filed Mar 15, 2013FY2011ended Dec 31, 2011filed Mar 13, 2012FY2010ended Dec 31, 2010filed Aug 4, 2011FY2009ended Dec 31, 2009filed Aug 4, 2011FY2008ended Dec 31, 2008filed Mar 13, 2012FY2007ended Dec 31, 2007filed Mar 13, 2012FY2006ended Dec 31, 2006filed Mar 13, 2012FY2005ended Dec 31, 2005filed Mar 13, 2012FY2004ended Dec 31, 2004filed Mar 13, 2012FY2003ended Dec 31, 2003filed Mar 13, 2012FY2002ended Dec 31, 2002filed Mar 13, 2012FY2001ended Dec 31, 2001filed Mar 13, 2012FY2000ended Dec 31, 2000filed Mar 13, 2012FY1999ended Dec 31, 1999filed Mar 13, 2012
Cash and equivalents1239511366113833642125676520201519182642—————————
Short-term investments76098150271735938118915614489466358593054———————————
Total current assets9171,10862879553647423420827415911313179765173———————————
Total assets1,4251,4028241,01584153429021129517011513383785378———————————
Total current liabilities20218010385723126223233322427757———————————
Long-term debt246935864474645403227150———————————————
Total liabilities2,0841,5371,2111,12359742030118518576474129757———————————
Stockholders’ equity(660)(135)(386)(108)244113(11)26110946992547048711015010010674108(92)(61)(37)(22)(9)
Shares outstanding (millions)1231181039585715955544240393624*13*————————————

Cash flow statement

Cytokinetics Inc. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 27, 2025FY2023ended Dec 31, 2023filed Feb 28, 2024FY2022ended Dec 31, 2022filed Mar 1, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 26, 2021FY2019ended Dec 31, 2019filed Mar 4, 2020FY2018ended Dec 31, 2018filed Mar 7, 2019FY2017ended Dec 31, 2017filed Mar 5, 2018FY2016ended Dec 31, 2016filed Mar 6, 2017FY2015ended Dec 31, 2015filed Mar 3, 2016FY2014ended Dec 31, 2014filed Mar 6, 2015FY2013ended Dec 31, 2013filed Mar 7, 2014FY2012ended Dec 31, 2012filed Mar 15, 2013FY2011ended Dec 31, 2011filed Mar 13, 2012FY2010ended Dec 31, 2010filed Aug 4, 2011FY2009ended Dec 31, 2009filed Aug 4, 2011FY2008ended Dec 31, 2008filed Mar 13, 2012FY2007ended Dec 31, 2007filed Mar 13, 2012FY2006ended Dec 31, 2006filed Mar 13, 2012FY2005ended Dec 31, 2005filed Mar 13, 2012FY2004ended Dec 31, 2004filed Mar 13, 2012FY2003ended Dec 31, 2003filed Mar 13, 2012FY2002ended Dec 31, 2002filed Mar 13, 2012FY2001ended Dec 31, 2001filed Mar 13, 2012FY2000ended Dec 31, 2000filed Mar 13, 2012FY1999ended Dec 31, 1999filed Mar 13, 2012
Operating cash flow(510)(396)(414)(300)(143)9(91)(101)(102)———(8)(33)(46)(45)8——————————
Capital expenditures254111491131321110001——————————
Free cash flow (CFO − capex)(535)(400)(416)(311)(191)(2)(94)(102)(105)———(8)(34)(46)(45)8——————————
Depreciation and amortization10101262211211001122——————————
Share repurchases———————————————————————————
Dividends paid———————————————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 9, 2024 to November 9, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$13M
17 sales by 5 insiders; officers and directors $13M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$52M
85 sales by 10 insiders; officers and directors $52M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Nov 3, 2026Malik Fady IbrahamEVP Research & Developmentoption exercise3,500$7.80$27K157,402Nov 3, 2026
Nov 3, 2026Malik Fady IbrahamEVP Research & Developmentopen-market sale10b5-13,500$62.93$220K153,902Nov 3, 2026
Nov 2, 2026Blum Robert IPresident & CEO, Directoroption exercise7,500$10.60$80K286,044Nov 2, 2026
Nov 2, 2026Blum Robert IPresident & CEO, Directoropen-market sale10b5-17,500$62.81$471K278,544Nov 2, 2026
Oct 20, 2026Malik Fady IbrahamEVP Research & Developmentoption exercise3,500$7.80$27K157,402Oct 20, 2026
Oct 20, 2026Malik Fady IbrahamEVP Research & Developmentopen-market sale10b5-13,500$64.01$224K153,902Oct 20, 2026
Oct 16, 2026Wysenski NancyDirectoraward97$63.92$6K34,089Oct 20, 2026
Oct 16, 2026Kaye Edward M. MDDirectoraward195$63.92$12K10,629Oct 20, 2026
Oct 16, 2026Harrington Robert ArthurDirectoraward195$63.92$12K22,127Oct 20, 2026
Oct 16, 2026Daly James MDirectoraward195$63.92$12K3,585Oct 20, 2026
Oct 16, 2026Wierenga WendellDirectoraward97$63.92$6K35,660Oct 20, 2026
Oct 16, 2026Henderson John TDirectoraward352$63.92$23K78,712Oct 20, 2026
Oct 12, 2026Blum Robert IPresident & CEO, Directoroption exercise7,500$10.60$80K286,044Oct 13, 2026
Oct 12, 2026Blum Robert IPresident & CEO, Directoropen-market sale10b5-17,500$62.88$472K278,544Oct 13, 2026
Oct 6, 2026Malik Fady IbrahamEVP Research & Developmentoption exercise3,500$7.80$27K157,402Oct 6, 2026
Oct 6, 2026Malik Fady IbrahamEVP Research & Developmentopen-market sale10b5-13,500$61.38$215K153,902Oct 6, 2026
Sep 28, 2026Blum Robert IPresident & CEO, Directoroption exercise7,500$10.60$80K286,044Sep 28, 2026
Sep 28, 2026Blum Robert IPresident & CEO, Directoropen-market sale10b5-17,500$65.46$491K278,544Sep 28, 2026
Sep 22, 2026Malik Fady IbrahamEVP Research & Developmentoption exercise3,500$7.80$27K157,402Sep 22, 2026
Sep 22, 2026Malik Fady IbrahamEVP Research & Developmentopen-market sale10b5-13,500$68.29$239K153,902Sep 22, 2026
Sep 15, 2026Landry Robert EDirectoropen-market sale10b5-11,000$72.13$72K8,184Sep 15, 2026
Sep 15, 2026Blum Robert IPresident & CEO, Directoropen-market sale10b5-1indirect97,926$69.33$7M0Sep 15, 2026
Sep 14, 2026Blum Robert IPresident & CEO, Directoroption exercise7,500$10.60$80K385,320Sep 15, 2026
Sep 14, 2026Blum Robert IPresident & CEO, Directoropen-market sale10b5-17,500$73.44$551K377,820Sep 15, 2026
Sep 14, 2026Blum Robert IPresident & CEO, Directorgift1,350$0.00—376,470Sep 15, 2026

Full insider history for Cytokinetics Inc., or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held CYTK in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded CYTK by quarter.

FundManagerQuarterValueSharesWeightMove
Baron Capital GroupRon BaronQ2 2026$852K10,0000.00%trimmed −56.5%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
CYTOKINETICS, INCORPORATED, CIK 1061983 on EDGAR
Extract generated
November 8, 2026
Withheld
1 line-years whose four quarters do not sum to the filed year: opex sga FY2018
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues, SalesRevenueNet
Cost of revenue: not filed
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense, SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 8, 2026.

JSON file
/data/financials/CYTK.json